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There is considerable evidence that cancer
is a disease produced by interactions
~between individual genetic susceptibility,
environmental exposure, and target-tissue
biology. The mutations in many tumors
have been identified in a proto-oncogene
or tumor-suppressor gene per se or at other
UGFI~ sites in the genome that alter their expres-
sion, e.g., translocations affecting proto-
................n
onco~~~~~genes. In some cases, such as p53
mutations of lung tumors, the mutation
spectrum is consistent with an exposure-
dependent etiology. In others such a pat-
tern is not evident. Interpreting the muta-
tion spectrum in genes causally related to
Or~ cancer requires understanding the role of
mutation spectra in tumor progression as
well as the basis of tissue differences in
metabolism , DNA repair, and routes of
di.... exposure. In addition, individual suscepti-
bility factors may affect all tissues of a per-
son. Recent reviews provide excellent
~overviews of these highly intertwined issues
~in molecular cancer epidemiology (1,2).
~In the past decade, a number of surro-
~OU~ gate biomarkers have been developed that
may be useful in epidemiologic studies to
~ascertain the contributions of environment
and genetics to the development of cancer.
These surrogates have the advantage that
they are not part of the tumor progression
process, and they have the potential to
~indicate various facets of exposure and
individual susceptibility. Biomarkers such
as sister chromatid exchange (SCE) and
.~DNA or protein adducts help measure
4~ exposure. Assays for chromosome translo-
cations or micronucleus formation each
monitor specific types of genetic damage
~~throughout the genome. Several assays for
specific gene somatic mutation detect the
biological consequences of exposure at the
gene level: the well-established assays for
mutation in lymphocytes at the hypoxan-
thine phosphoribosyltransferase (hprt, 3,4)
and HL-A (5,6) genes; in erythrocytes for
~~~the glycophorin A gene (7); and the newer,
less widely used lymphocyte mutation
assay for T-cell receptor genes (8,9).
The lymphocyte forward-mutation
Studies are unique in leading to both the
~somatic mutations. Each individual's
mutant frequency integrates his or her
exposure and susceptibility factors and pro-
vides a measurement based on the genetic
locus and cells involved. At the molecular
level, the hprt and HLA mutation assays
have different biases: the X-linked hprt
locus reports primarily nonrecombinigenic
mechanisms of gene inactivation such as
base substitutions, frameshifts, deletions,
and rearrangements (10), whereas the HLA
assay also reports recombination-based
mechanisms of mutation (-30%) (11).
Shifts in the hprt mutation spectrum have
been reported after radiotherapy; the inci-
dence of large deletion and rearrangement
mutations increased substantially, and an
altered mutation spectrum persisted in
some individuals for several years after
exposure (12,13). A similar shift in hprt
mutation spectrum after radiation expo-
sure has been seen in vitro (14,15).
Molecular definition of mutations
responsible for loss ofhprt function is pos-
sible due to recent technical developments.
The DNA sequence for the total genetic
locus is known (16). Polymerase chain
reaction (PCR) methods based on these
sequences have been developed for both
genomic DNA (17) and mRNA (18-20).
These methods have been used to deter-
mine mutations in the inherited Lesch
Nyhan disease (17,19,21,22), in cells treat-
ed in vitro with mutagens (23,24), and in
lymphocytes recovered from normal indi-
viduals (25-28).
The spectrum of the mutations recov-
ered at the hprt gene of control popula-
tions has the potential to reveal mecha-
nisms ofbackground mutation that lead to
gene inactivation independent of exposure
to exogenous agents and independent of
cancer progression per se. Such events have
been implicated in the genetic divergence
that occurs in precancerous proliferative
cells. The background mutation spectrum
will also provide a reference for studies of
exposed populations.
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Definition ofthe background mutation
spectrum for the human hprt gene oflym-
phocytes requires analysis of a large num-
ber of independent mutations. The hprt
gene is a broad mutation target, one that
can be inactivated by a large variety of
mutations. The mutation spectrum is not
yet saturated; new mutations are still being
found despite the collection of more than
1000 mutations at human hprt genes in in
vivo and in vitro studies (29). Population-
based studies are required to define the
background in vivo mutation spectrum
and the effects ofgenetic susceptibility and
exposure. In this report we begin to define
a population-based mutation spectrum of
the hprt gene using peripheral blood lym-
phocytes as an indicator for background
mutations.
Materials and Methods
The recruitment of subjects and methods
of obtaining samples were reviewed by
Institutional Review Boards at both Law-
rence Livermore National Laboratory and
the National Institute of Environ-mental
Health Sciences, and all subjects gave
informed consent before participating in
this study. The selection of subjects was
based on self-reporting ofno recent illness;
no exposure to radiation or chemicals
other than smoking or over-the-counter
medications; no prior history of heart dis-
ease, diabetes, tuberculosis, high blood
pressure, cancer, or hepatitis; no passive
cigarette/cigar/marijuana smoke exposure
at home; and age between 19 and 45 years.
All nonsmokers self-reported as never hav-
ing smoked regularly. This population has
been described in detail (30).
Isolation of Thioguanine-Resistant
Mutants
The frequency of thioguanine-resistant
mutants was determined by limiting dilu-
tion methods (30). To isolate mutants, we
cultured cells for up to 40 hr at 1 x 106
cells/ml with the mitogen phytohemagglu-
tinin (PHA; 1 fg/ml; HA17; Burroughs
Wellcome), then counted and plated them
in round-bottomed microtiter wells with
10% (v/v) lymphokine-activated killer cell
(LAK) supernatant (containing 15,000
U/ml human interleukin-2, serum-free
medium, and any factors produced during
the 3-4-day activation of peripheral blood
monocytes), reduced PHA (0.1 ,g/ml),
irradiated lymphoblastoid feeder cells
(5,000-20,000 viable irradiated-TK-
6/well; 5 Gy Cesium-137 delivered at 4.2
Gy/min), and f3-mercaptoethanol (50
mM), with or without thioguanine (1
,g/ml) selection (30-32). Throughout
this work the basal medium was RPMI
1640 supplemented with 5% fetal bovine
serum, 20% HL-1 (Ventrex Laboratories
Inc.), penicillin (100 U/ml), and strepto-
mycin (100 mg/ml). All cultures were
incubated at 370C at 5% CO2. Individual
thioguanine-resistant clones were expanded
to 5-40 x 106 cells in LAK supernatant-
supplemented medium with PHA at 0.1
pg/ml, by transfer to successively larger
numbers of wells, or larger wells, in the
presence of lethally irradiated lymphoblas-
toid cells (either TK6 or a derivative there-
of, 91-XC-4; that is, missing the X-linked
hprtsequences). We refreshed thioguanine
(1 ,g/ml) once at the first stage of cell
expansion after plating in microtiter wells.
We froze expanded clones in 8% dimethyl
sulfoxide, 20% fetal bovine serum, and
72% RPMI using a controlled freezing
program (Cryomed) and stored the clones
in liquid nitrogen. A single mutant from
each of 63 human subjects was studied,
hence the mutations reported are unam-
biguously independent events.
Preparation ofRNA and DNA
We prepared cytoplasmic extracts from
aliquots of frozen cells: 5-10 x 106 cells
were thawed, rinsed once in RPMI 1640
medium with 15% fetal bovine serum,
then washed twice with cold phosphate-
buffered saline (PBS). We suspended the
cells in 250 1 cold lysis buffer (10 mM
Tris-HCI pH 7.8, 150 mM NaCi) con-
taining 10 ,l RNAse Block II RNAse
inhibitor (Stratagene) per 250 W buffer.
We added 2% Nonidet P-40 (25 1/250 W
lysis suspension), vortexed the sample, and
held it on ice for 5 min to lyse cells. The
nuclei were pelleted by centrifugation at
40C. We transferred the supernatant con-
taining cellular RNA to clean tubes and
added 250 W extraction buffer (40 mM
Tris-HCI, pH 7.8, 40 mM EDTA, 0.7 M
NaCi, and 2% sodium dodecyl sulfate;
SDS. The suspension was extracted 5
times with phenol:chloroform:isoamyl
alcohol (25:24:1), then once with chloro-
form:isoamyl alcohol (24:1). We precipi-
tated RNA with two volumes of cold
100% ethanol. Samples were stored at
-200C. RNA was recovered by centrifu-
gation and washed twice with a 3:1 solu-
tion ofethanol: 0.1 M sodium acetate, pH
5.2. RNA pellets were dried and resus-
pended in diethylpyrocarbonate-treated
deionized water. We determined RNA
concentrations by optical density readings.
RNase Block II was added, and the RNA
samples were stored at -20°C or -800C.
We suspended the nuclear pellets in
750 ji lysis buffer (10 mM Tris pH 8, 0.4
M NaCl, and 2 mM EDTA), 125 ml pro-
teinase K digestion solution [1% sodium
dodecyl sulfate (SDS), 2 mM EDTA, and
250 mg Proteinase K], and 50 ml of 10%
SDS. The pellets were incubated at
60-65°C for 24-72 hr. We removed pro-
tein and SDS using salt extraction by the
addition of 750 ,l deionized water and
750 ml of saturated (6 M) NaCl. After
vigorous mixing for 30 sec, the precipitat-
ed SDS and proteins were removed by two
successive centrifugations. The DNA was
recovered by ethanol precipitation with 2
volumes of 100% ethanol at 40C. We
rinsed precipitated DNA twice with cold
70% ethanol. Pellets were air dried and
resuspended in TE (1OmM Tris, pH 8.0,
and 0.1 mM EDTA). We determined
DNA concentrations by OD readings.
Synthesis and Analysis ofcDNA
We synthesized cDNA by a modification
of the Superscript RNAse H-reverse tran-
scriptase reaction (RT Rx) procedure
(Gibco BRL) using 2 mg of cytoplasmic
RNA/20 p1 reaction. RNA, 0.2 jig oligo
d(T)18, and 0.5 ml RNAse Block II were
mixed in a total volume of 10.5 p1, heated
for 2 min at 950C, held at 450C while
adding 7.5 ml reaction mix [4 ,1 5X
Superscript reaction buffer, 2 p1 of 0.1M
dithiothreitol (DTT), 1.0 p1 ofdNTP mix
containing 25 pM each ofdNTP, and 0.5
pl RNAse Block II] and then adding 2.0 p1
of 200 U/ml RNase H-Superscript reverse
transcriptase. We incubated samples at
450C for 1 hr, then heated them to 90-
950C for 10 min before incubating them
20 min at 370C with 2 U RNAse H
(Gibco BRL) and storing them at -200C.
We carried out second-strand cDNA
synthesis and cDNA amplification by the
Taq DNA polymerase (AmpliTaq; Perkin
Elmer Cetus) using hprt-specific primers
(see Table 1) in two successive PCRs using
a Perkin-Elmer DNA Thermal Cycler. In
the first PCR amplification, we used three
pairs of primers in separate reactions: 1)
250 nM each of IRJ040 and IRJ041
amplified a partial adenosine phosphoribo-
syltransferase (APRT) cDNA, as a positive
control for RNA quality; 2) 62 nM each of
BRIN006 and IRJ048 amplified a 620 bp
hprt cDNA, approximately two-thirds of
the hprt cDNA from bp 140 through the
3' end; 3) 62 nM each of IRJ050 and
IRJ048 amplified the full-length hprt
cDNA. Reactions (50 mM KCl, 10 mM
Tris-HCI pH 8.3, 1.5 mM MgCl2, 150
PM each ofdNTP, 2 p1 ofthe reverse tran-
scrptase and one pair ofprimers) were cov-
ered with mineral oil, heated at 950C for 5
min, and held at 850C during the addition
and mixing of 1.25 U of Taq DNA poly-
merase into the reaction (total volume of
50 p1). The 35 cycles ofcDNA amplifica-
tion consisted of 1 cycle of 3-min denatu-
ration at 930C, 2-min primer annealing at
55°C, and 3-min elongation at 72°C, fol-
lowed by 24 cycles of 2-min denaturation
at 93°C, 1-min primer annealing at 550C,
and 3-min elongation at 720C, and then
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by the addition of 18 sec per round. We
visualized PCR products in 10 p1 of the
reaction on an agarose gel (2.5% Nusieve
plus 1% Seakem agarose in lx 90 mM
Tris-borate and 2.0 mM EDTA, pH 8.0),
stained with ethidium bromide.
In the second PCR amplification, 1/50
ofthe first PCR for full-length cDNA was
the template, and primers were nested with
respect to the first PCR primers in a 100 p1
reaction (50 mM KCI, 10 mM Tris-HCl
pH 8.3, 1.5 mM MgC12, 200 pM each of
dNTP, 0.25 RiM each of IRJ046 and
IRJ049, and 2 U of Taq DNA poly-
merase). We based the number (N) of
amplification cycles on the yield ofthe first
PCR: N = 35 cycles if a full-length cDNA
product was not visible; N = 20-25 cycles
if it was visible. Cycle 1 consisted of 4-
min denaturation at 930C, 2-min primer
annealing at 55°C, and 3-min elongation
at 720C, followed by (N- 1I) cycles of 2-
min denaturation at 930C, 1-min primer
annealing at 550C, and 3-min elongation
at 720C and the last 10 cycles with the
elongation step altered as above. Products
were evaluated as above.
We gel purified the hprt cDNA PCR
products and recovered them from gel
slices using GeneClean (BIO 101, Inc.).
Comparison of the cDNA template to
DNA size markers on agarose gels stained
with ethidium bromide was used to quan-
tify the cDNA.
Analysis ofGenomic DNA
Individual exons and flanking intron
sequences were simultaneously amplified
from genomic DNA (gDNA) by multiplex
PCR (mPCR) (17). We analyzed products
on 1.4% Seakem agarose gels stained with
ethidium bromide. Individual exon bands
were excised from the gel, minced in sterile
deionized water and refrigerated overnight.
We used aliquots of the eluted cDNA as
templates to amplify exon-specific frag-
ments and introduce the M13-21 "univer-
sal" priming sequence for sequencing the
product (17). The PCR products were
ethanol precipitated and quantified on
agarose gels before sequencing. In the case
of one mutant with no product in the
mPCR, template integrity and amplifiabili-
tywere confirmed using non-hprtprimers.
Sequencing
We used four fluorescent dye-labeled
primers for sequencing hprt cDNA (Table
1). We used IRJ 051 and IRJ 054 first;
IRJ 052 and IRJ 053 were used when nec-
essary to clarify results. For gDNA se-
quencing, we used the fluorescent dye-
labeled universal primer-21M13 from
Applied Biosystems Inc. For dideoxy
sequencing reactions, we used a modifica-
tion of the ABI Taq polymerase-based
cycle-sequencing protocol. Individual base
reactions were performed with larger vol-
umes: 14 p1 for A and C, each with 16.8
ng template, and 28 p1 for T and G, each
with 33.6 ng template. Dideoxy/deoxynu-
cleotide mixtures did not use modified
bases. Cycling times and temperatures
were 10 cycles with denaturation at 930C
for 2 min, annealing at 550C for 1 min,
and elongation at 720C for 2 min, fol-
lowed by 15 cycles with denaturation at
93°C for 30 sec and elongation at 700C for
1 min. We analyzed sequencing reaction
products of cDNA and gDNA templates
using the ABI 373A DNA Sequencer.
Sequence data were compared to wild-type
sequence using the SeqEd 675: DNA
Sequence Editor (Applied Biosystems Inc.).
Results
We cloned mutant lymphocytes by limit-
ing dilution from 63 donors, 34 ofwhom
were smokers (26 male smokers, 8 female
smokers) and 29 ofwhom were nonsmok-
ers (19 male nonsmokers, 10 female non-
smokers). The results ofanalysis of cDNA
and gDNA are summarized in Table 2 and
detailed in Tables 3-7. The results (Tables
2-7) are the conclusions of a series of
analyses. The strategy was to first analyze
the cDNA ofa mutant bysequencing it. If
the cDNA analysis was negative due to
absence of cDNA or inconclusive results,
gDNAwas studied.
The amount of cDNA synthesized in
the first hprt PCR reaction varied between
mutants, probably due to both experimen-
tal sources and mutation-induced change
in copy number of hprt RNA (mRNA).
Several controls for RNA and PCR condi-
tions were used. Synthesis of a short 3'
segment of aprt cDNA served as a control
for the integrity of the RNA and the re-
verse transcriptase reaction. Due to the
higher efficiency of 3' end cDNA synthe-
sis, a partial 3' hprt cDNA (two-thirds of
full-length cDNA) was synthesized to help
judge the presence or absence of hprt
cDNA. This reaction always gave a
stronger signal than the full-length prod-
uct. The cDNA ofsome mutants was not
visible as a full-length product until the
second, nested reaction. The use of the
full-length and two-thirds 5'-end primers
helped on occasions when a mutant was
deleted for the site of one of the 5' pri-
mers; for example, the full-length cDNA
was not made despite the presence of the
"two-thirds" product for SM16.1 4B2
(Tables 6 and 7), and the full-length
cDNA was present in the absence of the
two-thirds product of the exon 2-3 dele-
tion mutations such as of NM24.1 56A6
and NM30.1 17B (Tables 6 and 7).
In some cases cDNA sequencing iden-
tified a point mutation, but in others the
cDNA sequencing results were not conclu-
sive, and analysis of gDNA was required.
Simple exon skips (a clean loss of one or
multiple exons from the cDNA) or absence
ofexon sequences adjacent to introns were
taken as evidence of incorrect splicing of
the gene transcript. The mutation respon-
Table 2. Summary of independent hprt mutations
in lymphocytes of a control population
Mutation type Number
Base substitutions
Transitions 9
Transversions 18
Other: TGG to A 1
Total 28
Deletions/insertions
±1 bp 5
±2bp 3
-3bp 2
Small deletionsa 14
Large deletionsb 10
+30 bp duplication 1
Total 35
Total mutations 63
aDeletion of6-200 bp. bDeletion spanning one or more exons.
Table 1. Primers used for cDNA synthesis and sequencing
Application Product size Primer ID Primersequence
aprtcDNA, 3' end 230 bp IRJ 040 5'-ACT.ACA.TCG.CAG.GCC.TAG.ACT-3'
IRJ 041 5'-TTC.ATG.GTT.CCA.CCA.GTG.GCC-3'
hprtcDNA 877 bp IRJ 050a 5'-GCG.AAC.CTC.TCG.GCT.TT-3'
IRJ 048b 5'-AAG.CTC.TAC.TAAGCAGAT.GGC.CAC.AGAACT-3'
2/3hprtcDNAc 620 bp BRIN 006 5'-ACG.TCT.TGC.TCG.AGA.TGT.GAT.G-3'
IRJ 048 5'-ACG.TCT.TGC.TCG.AGA.TGT.GAT.G-3'
nested hprtcDNA 789 bp IRJ 046d 5'-CTC.TGC.TCC.GCC.ACC.GGC.TTC.CT-3'
IRJ 049e 5'-AAC.ATT.GAT.AAT.M.ACT.GGC.GAT-3'
hprtcDNA sequencing IRJ 051 5'-TGT.CAA.TAG.GAC.TCC.AGA.TGT.TTC-3'
IRJ 052 5'-TGT.AAG.GAT.TAT.ACT.GCC.TGA.CC-3'
IRJ 053 5'-TGT.AAT.TGA.GCA.CAC.AGA.GGG.CT-3'
IRJ 054 5'-TGT.AAA.GTT.GAG.AGA.TCA.TCT.CCA.C-3'
alRJO50, primerHT5', shortened by 1 bp (21). blRJ048, primer HT3', shortened by3 bp(21).
CPrimers amplify a 3' end fragment approximately2/3the length ofthe full cDNA. dlRJ046, primer 581 (19).
elRJ049, similarto primer PCR-2(20).
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sible for the missplicing phenotype was
sought by analysis of the indicated region
of gDNA. Multiplex PCR (17) revealed
deletions in exon-specific regions (as in
NM24.1 56A6). In some cases no gross
alteration of the gDNA was evident, and
specific exon/intron regions ofgDNA were
sequenced (17) to identify the mutation (as
in NM23.1 65B/C12 and SM6.1 24C9).
The base substitution mutations
described in detail in Tables 3 and 4 indi-
cate that hprt reports all possible types of
base substitution mutations. The relative
proportions of various base substitutions
reflect many factors, as discussed below.
The deletion mutations also display a
full range of mutation mechanisms as
described in Tables 5-7. Deletion sizes
stated in Table 6 are precise ifidentified by
sequencing cDNA (within exons) or esti-
mated by electrophoretic mobility when
identified by multiplex PCR. The ability
to detect deletions by mPCR, as was done
when no cDNA was made or the cDNA
had exon skips, depends on the primers
currently used and the associated PCR
fragment sizes (17). Changes in molecular
weight of a few percent can be seen in any
mPCR product, but the variation in size of
products means that sensitivityvaries byexon.
Discussion
The results presented demonstrate three
major points: the diversity of mechanisms
of gene inactivation mutation detectable
with the hprt locus ofhuman lymphocytes;
the fact that the sequence of a gene target
affects its mutation spectrum; and the chal-
lenge ofdistinguishing between the depen-
Table 3. Summary of base substitution mutations
Smokers Nonsmokers Total
Transitionsa 6 3 9
GCtoAT 4 3 7
ATto GC 2 0 2
Transversions 8 10 18
GCtoTA 1 2 3
GCtoCG 3 6 9
ATto TA 2 2 4
ATto CG 2 0 2
Other: TGG to A 1 1
Number of donors 14 14 28
Average 10 x 106 6 x 10-6
aThe base listed is in the nontranscribed strand
ofthe DNA.
Table 5. Distribution of deletion, insertion, and duplication mutations among types of donors
Type of mutation SM SF NM NF Total
Deletion of 1-3 bp 2 3 2 1 8
Deletion of 6-200 bpa 9 1 3 1 14
Deletion of? kilobaseb 4c 0 5 lC 10
Insertion of 1-2 bp 1 0 1 0 2
Duplication 0 0 1 0 1
Total 16 4 12 3 35
S, smoker; N, nonsmoker, M, male, F, female.
alncludes intraexonic deletions identified by sequencing cDNA and deletions of exonic regions detected
by gel analysis of multiplex poolymerase chain reaction products.
bLoss of one or more exonic region in multiplex polymerase chain reaction products.
COne mutation in which only one exon is lost.
Table 4. Base substitution mutations in human lymphocyte hprt mutants
Donor Mutant Mf,x106 Exon 2 Exon 3 Exon 4 Exon5 Exon 6 Exon 7 Exon 8 Exon9 Aminoacidchange/comments
SM23.1 25H11 7.1 C>G74a pro> arg
SM54.1 77B5 16.4 C>G 74a pro> arg
SM25.1 49A1 6.9 C>T74 pro> leu
NF27.1 5E2 1.9 TGG >A Term next codon
117-119C
SF15.1 43A8 16.2 T>G 146 leu > arg
SF9.1 33A10 7.0 G>T197 cys> phe
NM28.1 24E7 3.8 G>A 197 cys >tyr
SM5.1 14B6 2.1 G>A 208 gly> arg
NF13.1 33G8 6.6 C>G 2228 phe > leu
SF6.1 14E1 7.5 T>C 233 leu > pro
SM30.1 66D7 7.1 (G>A cln4:1l8IC Donor site (ex4 skip)
NM19.1 34F5 4.6 G>A400 glu >lys
SM40.1 59F3 15.9 A>T421 lys>term
NM27.1 9H9 7.0 T>A437a leu >term
NM11.1 55G2 8.8 T>A449a val >asp
SM52.1 18F6 14.5 T>G 449a val > gly
NM23.1 65B/C12 4.3 (G>C E6:-1)C Acceptorsite (ex6 skip)
NF9.1 34H3 5.1 C>G 486 ser> arg
NF4.1 24F5 11.8 C>T 508 arg >term (at CpG)
NM32.1 47H11 5.2 G>T529 asp > tyr
SM26.1 59B3 10.4 C>G 551 pro > arg
NF14.1 48D6 3.2 C>G 551 pro > arg
SM19.1 17B6 12.5 T>A 563 val > asp
NF15.1 27A7 7.4 G>C 574a ala > pro
NM44.1 68B3 11.3 G>C606a leu > phe
SF21.1 35D8 7.4 G>A617 cys>tyr
NF32.1 49B11 3.1 G>T617 cys > phe
SM6.1 24C9 11.6 (A>G E9:2)atc Acceptorsite
(> ex9 alternative splicing)
S, smoker; N, nonsmokers; M, male; F, female; Mf, mutant frequency. Bold type indicates base pairs where we have detected base substitutions, either the
same base change or a different base change, in more than one donor.
aNot previously seen to the best of our knowledge.
bComplex change: 1 base replaces 3.
CBase substitution in an intron at an mRNA splice site.
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Donor Mutant Mf,X106 Change Positiona
SM20.1 26 E3 5.6 del <50 bp cDNA did not include exon 1 or 12-20 bp upstream;
deletion <50 bp in exon 1 region of genomic DNAb
SM32.1 37E 10 6.0 del <54 bp cDNA deleted for bp-29to 108, including all of
exons 1+2 genomic DNA has a deletion <54 bp in
the exon 1 region
SM16.1 4B2 8.1 del <54 bp cDNA is synthesized but missing 5' primer sites,
giving a negative PCR resultforfull-length cDNA;
genomic DNA has a deletion of <54 bp ofthe exon 1
region
SM57.1 26H10 30.1 del >50 bp cDNA did not include exon 1; genomic DNA exon 1
region is deleted >50 but <185 bp
SM2.1 13E 2 13.6 del 10 bp cDNA deleted for bp 41-50, exon 2; deletion in exon
2 region in genomic DNA
NF28.1 57E 1 3.9 del 53 bp cDNA deleted for bp 42-94, exon 2; deletion in exon
2 region of one copy of genomic DNA
SF18.1 16B10 21.3 del 2 bp cDNA deleted for bp 56-57, exon 2
SM55.1 6C10 15.2 del 6 bp cDNA deleted for bp 103-108, exon 2
SM21.1 78E 2 4.8 ins 2bp cDNA has +GG inserted after 108, exon 2
SM3.1 5C8 4.4 del 1 bp cDNA deleted for bp 142, exon 3
SM29.1 46B4 6.5 del lbp cDNA deleted for bp 182, exon 3
NF8.1 15C8 10.1 del 2bp cDNA deleted for bps 288-289 or 289-290, exon 3
SF4.2 5G12 5.0 del 3 bp cDNA deleted for bps 301-303, exon 3
NM1.4 4E8 7.1 del lbp cDNA deleted for bp 354, exon 4
SM58.1 35H12 19.0 del -140 bp cDNA skips exon 4; in genomic DNA exon 4 region
is deleted -140 bp
NM36.1 65 E8 6.8 del -25 bp cDNA skips exon 4; in genomic DNA exon 4 region
has -25 bp deleted
NM26.1 5E 3 3.0 del 1 bp cDNA deleted for bp 440 or441 or442, exon 6
SM31.1 4F7 9.4 del 9 bp cDNA deleted for bps 466-474, exon 6; genomic
DNA has a small deletion in the exon 6 region
NM9.1 46C1 6.0 dup 30 bp cDNA hastandom duplication of bps 408-437 or
407-436 within exon 6; in genomic DNA exon 6 is
increased in size
SF29.1 49D11 7.8 del <167 bp cDNA skips exon 8; genomic DNA has a deletion in
the exon 7/8 region. Sequencing genomic DNA
found a deletion in intron 7 ending at E8:-5c
NM40.1 98B3 9.2 del <50 bp cDNA has deletion of 42 bp atthe 5' end of exon 8;
genomic DNA has a deletion in the exon 7/8 region
NM42.1 44C8 10.4 del <30 bp genomic DNA has a deletion in the exon 7/8 region
NM3.1 34 E12 4.8 ins 1 bp cDNA skips exon 8; Sequencing of genomic DNA
for exon 9 region found +1 bp (AT) inserted at
E9:-133 in intron 8
SF23.1 27A3 14.7 del 3 bp cDNA deleted for bps 622-624, or 623-625, exon 9
SM33.1 57A9 12.4 del -50 bp cDNA has 7 bp inserted after bp 609 between exons 8
and 9; exon 9 region has a deletion in genomic DNA
S, smoker; N, nonsmoker; M, male; F, female; Mf, mutantfrequency; PCR, polymerase chain reaction.
aBase 1 is the adenine of the protein synthesis initiation codon. Mutations are listed in order of exon
affected.
Exons and the flanking intron regions for each exon were amplified using sets of primers for multi-
plex PCR analysis (17).
cE8:-5 refers to the fifth base upstream of exon 8. Nomenclature from Rossi et al. (27).
dence of the mutation spectrum on the
reporter system used, exposure parameters,
and donor characteristics. Here we
emphasize the principles demonstrated by
our results rather than the numerical
aspects of our results. Our goal is com-
plete analysis of 200 independent muta-
tions from this population. Due to the
limits of analyses applied so far, detection
of deletion mutations, especially those of
males, may be preferentially ascertained
relative to base substitutions. The empha-
sis on analysis ofmutations in males repre-
sents the composition ofthe population we
have selected for ease ofmolecular analysis.
It has been possible to detect deletions in
the hprtgene offemales using mPCR when
a shift in mPCR fragment size has
occurred but not when a loss of exons on
the active X chromosome has occurred.
The heterozygosity of X-linked hprt se-
quences in mutants from females requires
analyses other than those used here when
the mutation is not defined in the cDNA.
No gender dependence ofmutant frequen-
cy response was detected in the larger pop-
ulation from which these donors were
drawn (30); hence, there is no quantitative
indication of a gender-specific mutation
spectrum.
A wide variety ofmutations that inacti-
vate the hprt gene have been found in this
population. All possible base substitutions
were found. Among the base substitu-
tions, mutations at GC base pairs predom-
inate. This imbalance may be due to the
multiplicity of events that affect GC base
pairs, e.g., depurination of adducted gua-
nines, deamination of cytosine, misincor-
poration at adducted guanines, and in part
to the mutation-sensitive sequences in
hprt, as discussed below. Short (one to two
base pairs) insertions and deletions charac-
teristic of polymerase errors have been
noted in exons and, in one case, in an
intron. Deletions have been found
throughout the gene; included were events
ofvaried size, though only one case oftotal
gene deletion was seen. Sequence duplica-
tion was also seen only once.
The variety of mutations reflects the
wealth of vulnerable features of the hprt
gene and its protein product and provides
insight into facets of the mutation spec-
trum that may be used in comparisons of
populations. Interspecies comparisons of
the amino acid sequence of hprt demon-
strate considerable conservation, indicating
areas most likely to be associated with
functional domains or other critical fea-
tures (33,34). It is striking that the TA to
GC change at base 449 leading to a valine
to glycine amino acid substitution resulted
in an hprt-deficient phenotype. This con-
servative amino acid substitution indicates
that this must be a critical residue in the
protein; all missense mutations that occur
at this residue should be recoverable as
hprt-deficient mutations and should be in
the hprt mutation spectrum. Similarly,
proline residues seem to critically affect the
the hprt polypeptide; five mutations that
lead to missense replacements of proline
were identified. The specific base substitu-
tions that produced these changes included
four cases ofGC to CT transversion, lead-
ing to a proline to arginine mutation, and
one case ofa GC to AT transition, leading
to a proline to leucine mutation. The pro-
line-associated transversion mutations were
responsible for four ofthe nine GC to CG
transversions and largely defined one fea-
ture ofthe mutation spectrum in this pop-
ulation. The relative proportion ofGC to
AT to GC to CG mutations at these sites
may discriminate between conditions that
lead to transitions rather than transver-
sions. The tetrameric state of the HPRT
enzyme (35) also is a target of mutation.
Required cross-linking by cysteines may be
the reason that 4 of the 28 base substitu-
tions (at bases 197 and 617) led to mis-
sense substitutions for cysteine. Both GC
to TA and GC to AT mutations were
recovered, and there is potential to look at
the relative proportions ofthese in relation
to exposure or other variables. Base pair
617 is a hot spot; mutations have been
recovered in other in vivo human hprt
studies, both as lymphocyte mutations
(25,26) and as inherited hprt genes of
Lesch Nyhan patients (19). In contrast,
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Table 7. Mutations spanning exons and/or introns in genomic DNA
Donor Mutant Mf, x106 Position
NM24.1 56A6 5.8 cDNA skips exons 2-3; missing exons 2 + 3 in genomic DNA: is not a
recombinase eventa
NF33.1 59B4 6.9 cDNA skips exons 2-3; missing exons 2 + 3 in genomic DNA of one
gene copy: is a recombinase mediated eventa
NM30.1 17B2 4.6 cDNA skips exons 2-3; missing exons 2 + 3 in genomic DNA: is a
recombinase-mediated eventu
SM8.1 25G5 5.4 no cDNA made; missing exons 4-9 in genomic DNA
NM29.1 55A5 5.0 no cDNA made; missing exons 4-9 in genomic DNA
SM50.1 44H5 14.9 no cDNA made; missing exons 4-9 in genomic DNA.
NM37.1 77H8 3.7 cDNA skips exon 5; missing exon 5 in genomic DNA.
SM14.1 14G1 6.6 cDNA skips exons 5-6; missing exons 5-6 in genomic DNA
SM28.1 34A7 11.5 cDNA skips exon 6; missing exon 6 region in genomic DNA
NM31.1 24 E8 5.4 no cDNA made; missing all exons in the genomic DNA
S, smoker; N, nonsmoker; M, male; f, female; Mf, mutantfrequency; PCR, polymerase chain reaction.
aAnalysis of recombinase role in exon 2-3 deletions from Fuscoe et al. Fuscoe (36).
the absence in this study ofmissense muta-
tions affecting exons 1 and 4 indicates that
the HPRT enzyme is relatively tolerant of
amino acid changes in these regions.
Introns are also important targets of
mutation due to their role in splicing
mRNA. Both deletion and base substitu-
tion mutations in the eight introns may
lead to missplicing and hprt deficiency
(26-28). The evolution of intron
sequences is responsible for one class of
deletion mutations. Introns 1 and 3 have
sequences sufficiently like the consensus
sequences for the recombinase involved in
rearrangement ofT-cell receptor genes and
antibody genes that aberrant recombinase
recombination produces large deletions
encompassing exons 2 and 3 in a small per-
centage ofmutants (36,37). The frequen-
cy of these recombinase-dependent events
is not known to be affected by exposures to
toxic agents and is believed to represent the
persistence of mutant lymphocytes pro-
duced during early T-cell development
(38). These exon 2-3 deletion events
therefore are part of the background spec-
trum forhuman lymphocyte hprtmutation.
Mutations at CpG sequences do not
dominate the hprt mutation spectrum. In
this regard, hprt mutations are unlike
mutations of p53 of some tumors (39),
APC genes in colorectal tumors (40), and
genes associated with human genetic dis-
eases (41,42). The low incidence ofCpG-
associated mutations is a benefit to somatic
mutation studies, as these mutations do
not dilute other, potentially more informa-
tive, events. This low incidence suggests
lack ofmethylation ofcontrol elements in
hprton the active Xchromosome, as hprtis
a continuously transcribed housekeeping
gene (43). One mutation at a CpG was
identified in this study, a GC to AT at base
pair 508. It may be an event independent
ofthe CpG sequence, as GC to AT was the
most common class of transition. It could
also be the product of mitotic recombina-
tion with a mutated hprtgene on the inac-
tive X; the donor was a female.
The mutations reported here are each
from a different human donor, hence they
sample somatic mutations in a population.
This approach, though burdensome,
ensures that the mutations are biologically
independent. This approach also provides
the opportunity to relate mutation spec-
trum to mutant frequency, exposure histo-
ry, and potentially, individual susceptibili-
ty genotype. Any set ofmutations collect-
ed is a reflection ofthe population studied.
Previous studies of hprt mutations in
human lymphocytes have focused on a sin-
gle or small number of donors, with the
intent of determining the types of muta-
tions present, not ofrelating these to pop-
ulation characteristics (25-28). Published
reports have not always made clear which
mutants came from the same donor. An
hprt database (29) is being compiled to
provide this information.
Mutant frequency provides an integrat-
ed measure ofindividual response to smok-
ing and other exposure and endogenous
factors. The population studied here is well
defined (30). The age range was quite nar-
row, 19-45 years, averaging 32 years. The
population was prescreened to ensure that
smoking was the primary exposure vari-
able. Factors that affect mutant frequency
in this population included age, years of
smoking, and the proportion of lympho-
cytes that form clones or cloning efficiency
(30). The cloning efficiency may relate
mutant frequency to cell proliferation,
with more mutants forming when more
cell proliferation occurs. Ifthis hypothesis
is valid, then proliferation-dependent
mechanisms of mutation may be larger
contributors to the mutation spectrum in
individuals with higher mutant frequency
in association with lower cloningefficiency.
Mutant frequency is useful in judging
the likelihood that an exposure or some
other factor has affected mutation. The
mutant frequencies of donors from whom
base substitution mutations were isolated
mimick that of the overall population,
being higher in smokers (10 x 10-6) than
nonsmokers (6 x 10-6). The smokers were
heterogeneous in their response to smok-
ing as measured by the frequency of hprt
mutant lymphocytes, however. Mutation
spectra of smokers with high and low
mutant frequencies will differ to the extent
that smoking changes the types of muta-
tions as well as the frequency ofmutation.
Though the numbers are small and the sta-
tistical significance of the difference is
small (p = 0.2 for X2 analysis), it is intrigu-
ing that more base substitution events
occurred at AT base pairs in smokers
(6/14) than in nonsmokers (2/14). This
pattern could relate to a recent observation
that repair in human lymphoblastoid cells
of 04-ethylthymine and 02-ethylthymine
was less efficient than repair of 06-ethyl-
guanine (43). The average mutant fre-
quency of these eight donors with muta-
tions at AT base pairs was 12 x 10-6, due
largely to the six smokers whose mutant
frequency averaged 13 x 10-6. It has been
noted that p53 mutations in leukemias and
lymphomas show relatively more p53
mutations at AT base pairs (39). Differ-
ences in exposure and tissue biology proba-
bly contribute to these observations. Dose
dependence of the mutation spectrum has
been suggested by in vitro hprt mutation
studies with benzo[a]pyrene (23,44).
A long-term goal ofmolecular epidemi-
ology studies such as this one is to identify
the impact on health risk ofexposure vari-
ables, genetic susceptibility factors, and
interactions between them. Given the
complexities of mutation mechanisms per
se and ofeach potential genetic target and
cell type, studies of mutation spectra in
any system will require population studies
with analysis of large numbers of muta-
tions. There is potential for a disease
process to progressively alter the biology of
the cells it affects. Surrogate cells therefore
provide a valuable perspective on mutation
mechanisms, one different from intermedi-
ate markers ofdisease. The studies of hprt
mutation in lymphocytes reported here
represent one such approach. As more is
learned about the mutation spectrum of
this locus, increasingly more efficient and
powerful methods for comparative popula-
tion studies will be possible.
Note added inproof. Mutations from 9
smokers and 12 nonsmokers have recently
been reported byVrieling et al. in Carcino-
genesis 13:1625-1631(1992)
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